Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 253-257

  Kaira, Kyoichi ^a   Sunaga, Noriaki ^a   Yanagitani, Noriko ^a   Imai, Hisao ^a   Utsugi, Mitsuyoshi ^a   Iwasaki, Yasuki ^a   Shimizu, Kimihiro ^a   Iijima, Hironobu ^b   Tsurumaki, Hiroaki ^b   Tomizawa, Yoshio ^b   Hisada, Takeshi ^a   Ishizuka, Tamotsu ^a   Saito, Ryusei ^b   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b National Nishigunma Hospital   (Japan)

Author keywords

Carboplatin; Non small cell lung cancer; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; MEDICAL RESEARCH; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OXONIC ACID; TEGAFUR; THROMBOCYTOPENIA;

EID: 77950458481     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.06.024     Document Type: Article

References (17)

1. Shirasaka T., Shimamoto Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7:548-557.
2. Tatsumi K., Fukushima M., Shirasaka T., Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987, 78:748-755.
3. Takechi T., Fujioka A., Matsushima E., Fukushima M. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 2002, 38:1271-1277.
4. Takechi T., Nakano K., Uchida J., Mita A., Toko K., Takada S., et al. Antitumour activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997, 39:205-211.
5. Kawahara M., Furuse K., Segawa Y., Yoshimori K., Matsui K., Kudoh S., et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001, 85:939-943.
6. Ichinose Y., Yoshimori K., Sakai H., Nakai Y., Sugiura T., Kawahara M., et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004, 10:7860-7864.
7. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002, 346:92-98.
8. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C., Blum R.H., Green M.D., Mason B., et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989, 7:1602-1613.
9. Kaira K., Sunaga N., Yanagitani N., Imai H., Utsugi M., Shimizu Y., et al. A phase I dose escalation study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Anticancer Drugs 2007, 18:471-476.
10. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748-1756.
11. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
12. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcaitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18:317-323.
13. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:3852-3859.
14. Ozawa Y., Inui N., Naitoh T., Yasuda K., Nagayama M., Shirai T., et al. Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer. Lung Cancer 2009, 63:68-71.
15. Watanabe A., Taniguchi M., Yamashita T., Ueda M., Abe T., Kusumi T., et al. Phase I/II study of S-1 combined with carboplatin in recurrent and/or metastatic head and neck cancer as outpatient chemotherapy. Head Neck 2006, 28:620-625.
16. Tamura K, Okamoto I, Ozaki T, Kashii T, Takeda K, Jobayashi M, et al. Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Eur J Cancer; in press.
17. Saka H., Kitagawa C., Yamamoto M., Suzuki R., Taniguchi H., Ichikawa M., et al. Phase I/II trial of TS-1 plus carboplatin in patients with advanced non-small cell lung cancer: final report of a Central Japan Lung Study Group Trial-CJLSG 0402. Proc Am Soc Clin Oncol 2008, 26:15S.